[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 653,171
  • Shares Outstanding, K 77,944
  • Annual Sales, $ 311,710 K
  • Annual Income, $ 163,060 K
  • EBIT $ 217 M
  • EBITDA $ 232 M
  • 60-Month Beta 1.50
  • Price/Sales 2.07
  • Price/Cash Flow 4.04
  • Price/Book 1.41

Options Overview Details

View History
  • Implied Volatility 42.15% (-0.87%)
  • Historical Volatility 58.94%
  • IV Percentile 2%
  • IV Rank 6.80%
  • IV High 109.79% on 04/09/26
  • IV Low 37.21% on 08/26/26
  • Expected Move (DTE 16) 0.64 (7.54%)
  • Put/Call Vol Ratio 1.75
  • Today's Volume 382
  • Volume Avg (30-Day) 1,126
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 31,389
  • Open Int (30-Day) 38,286
  • Expected Range 7.81 to 9.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 1
  • High Estimate $-0.05
  • Low Estimate $-0.05
  • Prior Year $0.57
  • Growth Rate Est. (year over year) -108.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.10 +19.65%
on 08/12/26
8.98 -5.40%
on 08/13/26
+0.96 (+12.82%)
since 07/31/26
3-Month
7.10 +19.65%
on 08/12/26
9.09 -6.50%
on 06/11/26
+0.32 (+3.98%)
since 06/02/26
52-Week
6.13 +38.69%
on 03/06/26
14.66 -42.05%
on 09/03/25
-6.15 (-41.97%)
since 09/02/25

Most Recent Stories

More News
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

WFC : 89.29 (+2.59%)
CRMD : 8.58 (+2.39%)
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 8.58 (+2.39%)
CorMedix: Q2 Earnings Snapshot

CorMedix: Q2 Earnings Snapshot

CRMD : 8.58 (+2.39%)
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

‒ Q2 2026 Consolidated Revenue of $101.9 million ‒

CRMD : 8.58 (+2.39%)
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

‒ Q2 2026 Consolidated Revenue of  $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises...

CRMD : 8.58 (+2.39%)
CorMedix Raised Guidance in May, but That Was Before August Expectations Reset

Barchart Research What to Expect from CRMD Earnings CRMD Generated August 12, 2026 Current Price $7.10 EPS Estimate $$0.26 Consensus Rating Moderate Buy Average Move 17.12% CorMedix Raised Guidance in...

CRMD : 8.58 (+2.39%)
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for...

CRMD : 8.58 (+2.39%)
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the...

CRMD : 8.58 (+2.39%)
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the...

CRMD : 8.58 (+2.39%)
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the...

CRMD : 8.58 (+2.39%)

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed...

See More

Key Turning Points

3rd Resistance Point 8.83
2nd Resistance Point 8.66
1st Resistance Point 8.52
Last Price 8.58
1st Support Level 8.21
2nd Support Level 8.04
3rd Support Level 7.90

See More

52-Week High 14.66
Fibonacci 61.8% 11.40
Fibonacci 50% 10.39
Fibonacci 38.2% 9.39
Last Price 8.58
52-Week Low 6.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.